Chronological age represents the single greatest risk factor for human disease. Cellular senescence, which is a permanent state of cell cycle arrest induced by cellular inflammation and stress, has recently emerged as a fundamental component of the mechanism of aging that contributes (by secretion of inflammatory molecules) to age related diseases, including cancer, atherosclerosis and osteoarthritis.

Numeric Biotech develops therapeutic compounds that selectively eliminate senescent cells (SNC’s). These therapeutic compounds were tested in various ex-vivo and animal models that demonstrated reversal of the underlying disease process, which may have a preventative effect regarding oncogenesis and the inception of chronic degenerative target organ diseases.

Striking pre-clinical in-vivo results were published in peer reviewed scientific journals.

In vivo effect of NBT-103 on senescent cells

In vivo phenotype effect of NBT-103


Numeric Biotech